Medical Translation Quote Pricing: The Regulatory Cost Behind ISO 17100 and MDR Submissions

Why Your Medical Translation Quotes Differ by 300%

Last month, an IVD client brought us three quotes for the same EU IVDR clinical evaluation report. Vendor A: $0.08/word. Vendor B: $0.18/word. Vendor C: $0.30/word. He asked: where does the gap come from?

I answer this question dozens of times a year. Here is the breakdown.

A medical translation quote is never just word count multiplied by rate. It reflects regulatory liability, terminology assets, and verification workflows.

Four Hard Costs That Drive Translation Company Quotes

1. Translator Qualifications and Domain Fit

A general business translator with a CATTI Level 2 certificate can handle a standard press release. But an FDA 510(k) Summary or an MDR 2017/745 Annex II technical file requires a translator who understands both medicine and regulatory reading conventions. There are fewer than a few thousand such linguists globally.

We have tracked this internally: a competent medical device regulatory translator needs at least 18 months of ramp-up. They must navigate IMDRF terminology, historical GHTF documents, and the review preferences of individual Notified Bodies. That cost lands in the translation price.

2. Terminology Database and Translation Memory Reuse

This is the most overlooked variable in procurement.

If your product line already has a terminology base maintained for three years, a new IFU translation may hit 40%-60% reuse. The quote drops accordingly. Conversely, if you are preparing an MDR technical file for the first time, terminology starts from zero. The translator must cross-reference MedDRA, SNOMED CT, and WHO ICD mappings. Those hours are real.

Project Stage	Terminology Status	Typical Reuse	Impact on Quote
First translation	None	0%	Base rate +15%-25%
Product line expansion	Core terms exist	30%-50%	Base rate -10%-20%
Annual/periodic update	Full TM + termbase	60%-80%	Base rate -30%-45%

3. Regulatory Verification and Dual Review

ISO 17100:2015 mandates translation, revision, review, and final verification. In the medical sector, add a clinical compliance check.

That means an MDR clinical evaluation report passes through at least three people: translator, domain expert, and regulatory QA. This is not bureaucracy. It is the survival mechanism when a Notified Body issues a deficiency letter. We have seen too many submissions returned for terminology inconsistency.

4. DTP and eCTD Publishing

eCTD submissions are not ready to file after translation. They require PDF bookmarks, hyperlinks, and font embedding per ICH M8. Multilingual versions add RTL language compatibility (e.g., Arabic). This work is billed per page, not per word.

Hidden Risks in Translation Pricing Standards

A low quote does not always mean efficiency. Sometimes it means the vendor shifted risk to you.

• Skipping terminology validation: "Adverse event" translated inconsistently within the same document. A Notified Body will flag it immediately.
• Using non-native translators: Chinese technical documents translated into English by non-native speakers. It reads "acceptable" until a reviewer notices the unnatural phrasing.
• No back-translation: For labels and IFUs, back translation is the standard method for verifying semantic accuracy. Skipping it gambles with patient safety.

These hidden costs return as deficiency letters, rework, or recalls.

How to Judge Whether a Translation Quote Is Reasonable

Do not compare unit rates alone. Ask four questions:

1. What is the translator's medical or regulatory background? Can they provide an anonymized CV?
2. Who owns the termbase and translation memory? Can you export them after the project?
3. Who performs revision and QA? Are they independent of the translation team?
4. Can you provide an ISO 17100 conformity statement?

If the answers are vague, a low price is not worth the contract.

A Real Cost Comparison

Last year we took over a project: an orthopedic implant manufacturer's MDR technical file, 120,000 words. The previous vendor quoted $12,000. It received three deficiency letters and delayed the submission by four months.

We rebuilt the termbase, ran back-translation validation, and handled eCTD publishing. Total cost: approximately $32,000. It looks like more than double. But the client calculated the four-month delay against market loss. The difference was trivial.

Translation quotes must be measured against the compliance timeline.

If you are preparing multilingual documents for MDR, IVDR, or FDA submissions, send us the document types and target languages. The Linguist team will provide a transparent cost breakdown based on actual scope. No low-price traps. Only translations that pass review.